Home Actualité internationale CM – Galectin stocks rise in early-stage belapectin cancer study data
Actualité internationale

CM – Galectin stocks rise in early-stage belapectin cancer study data

Galectin Therapeutics (GALT) shares rise more than 60% during pre-trading after the company received positive results from its early-stage study of belapectin in certain ...

Keywords:

Galectin Therapeutics Inc.,Pembrolizumab,Head and neck cancer,Clinical trial,Melanoma,NASDAQ:GALT,Metastasis,Stock,Galectin Therapeutics Inc., Pembrolizumab, Head and neck cancer, Clinical trial, Melanoma, NASDAQ:GALT, Metastasis, Stock,,

[quads id=1]